Physician profile
Terry V Arnold
NPI 1326108887
$19,634.24
in general payments reported to CMS, 2019-2025
66 companies · $3,178 in 2025
The $3,178 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,027 · 2020: $2,459 · 2021: $2,575 · 2022: $2,602 · 2023: $3,075 · 2024: $2,718 · 2025: $3,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,884 · Education: $61.95 · Consulting Fee: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,883.75 |
| Education | $61.95 |
| Consulting Fee | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,312.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,882.48 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,466.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,416.70 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $1,373.50 | 2019-2025 | |
| Glaxosmithkline, LLC. | $833.90 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $810.01 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Merck Sharp & Dohme LLC | $714.78 | 2020-2025 | Verquvo, Belsomra, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $678.21 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $598.86 | 2019-2025 | Rexulti, Nuedexta |
| Amgen INC. | $540.85 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $499.98 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $462.83 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Astellas Pharma US INC | $461.26 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $404.16 | 2019-2023 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $341.01 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $313.50 | 2019-2024 | Xarelto |
| Avanir Pharmaceuticals, INC. | $276.08 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $275.97 | 2019-2024 | Linzess |
| Sunovion Pharmaceuticals INC. | $250.96 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $239.72 | 2019-2023 | |
| Vanda Pharmaceuticals INC. | $238.58 | 2025 | Fanapt, Hetlioz |
| Amarin Pharma, INC. | $209.54 | 2019-2022 | |
| Mylan Specialty L.P. | $200.71 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $196.18 | 2019-2025 | Belbuca |
| E.R. Squibb & Sons, L.L.C. | $183.17 | 2019-2025 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $182.08 | 2021-2023 | |
| Lundbeck LLC | $178.75 | 2023-2025 | Rexulti |
| Almatica Pharma LLC | $172.17 | 2022 | |
| Phathom Pharmaceuticals, INC. | $167.87 | 2025 | Voquezna |
| Corium, LLC | $131.84 | 2022-2023 | Adlarity, Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $117.56 | 2021-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $95.41 | 2024-2025 | Gemtesa |
| Daiichi Sankyo INC. | $92.08 | 2019-2023 | Injectafer |
| Avion Pharmaceuticals | $86.07 | 2020-2022 | |
| Biogen, INC. | $81.56 | 2021-2022 | |
| Exact Sciences Corporation | $76.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $73.41 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $72.81 | 2021 | |
| Shield Therapeutics INC | $68.58 | 2023-2025 | Accrufer |
| Idorsia Pharmaceuticals US INC | $63.74 | 2023-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $59.94 | 2019-2020 | Xyosted |
| Xeris Pharmaceuticals, INC. | $56.01 | 2022-2023 | Gvoke Hypopen |
| Ardelyx, INC. | $55.25 | 2025 | Ibsrela |
| Esperion Therapeutics, INC. | $54.40 | 2020-2023 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $53.63 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $52.36 | 2019-2021 | |
| Genentech USA, INC. | $51.95 | 2019-2021 | |
| Zyla Life Sciences, INC. | $41.94 | 2019 | |
| Abbott Laboratories | $35.01 | 2022-2024 | Freestyle Libre 2 |
| Radius Health, INC. | $34.21 | 2025 | Tymlos |
| Paratek Pharmaceuticals, INC. | $31.84 | 2023-2024 | Nuzyra |
| Sanofi Pasteur INC. | $28.96 | 2019-2023 | |
| Baxter Healthcare | $25.00 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Antares Pharma, INC. | $24.43 | 2023 | Nocdurna, Tlando, Xyosted |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.60 | 2022 | |
| Halozyme INC | $21.44 | 2023 | |
| Acadia Pharmaceuticals INC | $18.13 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $16.74 | 2023 | Inpefa |
| Cmp Pharma, INC. | $16.44 | 2021 | |
| Irhythm Technologies, INC. | $16.05 | 2022 | |
| Medicure Pharma INC. | $15.58 | 2022 | |
| Edwards Lifesciences Corporation | $15.36 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Impel Pharmaceuticals INC. | $15.17 | 2023 | Trudhesa |
| Phadia US INC. | $15.08 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.